Moenomycins are phosphoglycolipid antibiotics and the only known natural product inhibitors of peptidoglycan glycosytransferases (PGTs). Techniques that would allow facile diversification of the moenomycin structure would facilitate the development of novel antibiotics, which are urgently needed in the wake of multidrug resistant bacterial infections. The cloning and initial characterization of the moenomycin biosynthetic genes has already redefined the minimal moenomycin pharmacophore and now opens the door for the biocombinatorial generation of bioactive moenomycin fragments. Here, we highlight the importance of research on the genetic mechanisms that regulate moenomycin biosynthesis and that confer moenomycin resistance to bacteria in the development of novel anti-infectives based on PGT inhibition.
Introduction
The alarming rise of multiresistant bacterial infections over the past decade has renewed interest in the field of antibiotic research (Walsh and Wright, 2009) . Along with the discovery of new targets and novel antibiotics, genetic engineering of known natural product antibiotics is a possible source for new chemotherapies. Since natural products produced by microorganisms and plants evolved to function in environments very different from that of the human body, their structures often need to be modified to improve in vivo activity and/or pharmacology. Although chemical synthesis has been widely used to achieve such structural improvements (Welzel, 2005) , biology-based approaches to manipulate complicated natural product chemistry are now competitive with these chemical methodologies in many cases (Chen et al., 2003) . In these approaches, genes or enzymes for natural product biosynthesis are 'mixed' to generate novel metabolic pathways, ultimately leading to a library of closely related compounds. It is essential to consider combinatorial biosynthesis not only as a method of 'assembly' of novel analogs but also as a way to obtain large amounts of bioactive compounds cheaply.
Here, recent advances in chemical and biological studies on phosphoglycolipid antibiotics moenomycins (Mm's; Figure 1 ) will be reviewed. The prototypical member of this group, moenomycin A (MmA), was described four decades ago and was shown to display very potent antibacterial activity against a range of Gram-positive bacteria (Huber, 1979 ). Mm's (synonyms: flavomycin, bambermycins, flavophospholipol) are the only known natural products that directly inhibit peptidoglycan glycosyltransferase (PGT), the enzyme involved in the penultimate step of bacterial cell wall biosynthesis (Figure 2 ). Despite the unique structure and mode of action of MmA (Ostash and Walker, 2005) , the compound has poor pharmokinetics, and no moenomycin-based antibiotics are used clinically. This is because the chemical synthesis of Mm's is a daunting task (Welzel, 2005; Taylor et al., 2006) and the biosynthetic genes were only recently discovered (Ostash et al., 2007) . Advances in understanding the genetics of MmA production provide new tools to produce structurally complex moenomycin derivatives as well as to unravel the details of how bacteria regulate production and resistance to such potent antibiotics.
Moenomycins: occurrence in nature, structural features, and relationship between structure and activity Mm's are a small family of closely related compounds produced by actinomycetes, mostly of the genus Streptomyces. However, Actinoplanes teichomyceticus, an actinomycete strain best known for the production of lipoglycopeptide antibiotic teicoplanin, has also been shown to accumulate a phosphoglycolipid, teichomycin A 1 (Bardone et al., 1978) .
The phosphoglycolipid family is exemplified by MmA (Figure 1 ), a major representative of the moenomycin complex produced by Streptomyces ghanaensis. The structure of MmA features elements rarely found in the secondary metabolites of bacteria. The C 25 lipid chain is of isoprenoid origin and undergoes an unusual rearrangement in the process of biosynthesis (Neundorf et al., 2003) . The MmA pentasaccharide moiety contains heavily modified sugars and is further decorated with a pentacyclic chromophore, unit A (Figure 1) . A phosphoglycerate, unit G, joins the pentasaccharide and lipid portions of MmA and is the most unique structural characteristic of the phosphoglycolipids (Welzel, 2005) . Naturally occurring moenomycins differ mainly in the structure of carbohydrate unit F (attached to phosphoglycerate; Figure 1 ) and the lipid moiety. The latter can be either moenocinol (in moenomycins from S. ghanaensis, see lipid a, Figure 1 ) or diumycinol (He et al., 2000) , a derivative of moenocinol with terminal six-membered ring (see lipid b, compound 3; Figure 1 ). Other Mm derivatives lack the chromophore unit A or unit D sugar. Many of the known phosphoglycolipid antibiotics were isolated three to four decades ago and their exact chemical structures are not known (Welzel, 2005) .
MmA blocks cell wall biosynthesis by directly inhibiting PGTs from both Gram-negative and Gram-positive bacteria and displays strong antibacterial activity against Gram-positive bacteria, including many vancomycin-and methicillinresistant strains (Goldman et al., 2000) . With an IC 50 value of 0.01-0.1 mg/l (Goldman et al., 2000) , moenomycin is 1000 times more potent than vancomycin, the antibiotic of 'last resort'. As MmA effectively kills 'leaky' Escherichia coli strains, which have defects in the outer membrane (Eggert et al., 2001) , it is assumed that the outer membrane of healthy Gram-negative bacteria prevents MmA from reaching its target. Mm's are also known to kill E. coli cells carrying conjugative R-plasmids more efficiently than their plasmidless parent strains (Iyobe et al., 1971) . Conjugative transfer of DNA in enterobacteria requires the formation of pili, syringe-like organelles that protrude from the outer membrane and thus cause its restructuring, which might help MmA gain access to the periplasm. Although the mechanism has not been determined, MmA is well known to inhibit the frequency of the transfer of conjugative plasmids both in vitro and in animals (Riedl et al., 2000; Pfaller, 2006) . Given the fact that plasmid-based transfer of resistance genes has significantly decreased the efficacy of many antibiotics, this property is potentially clinically relevant.
Crystal structures of moenomycin complexed with Staphylococcus aures PBP2 and Mtg proteins, E. coli PBP1B, and the Aquifex aeolicus PBP1A PGT domain have revealed the interactions between moenomycin and its target that make it an unparalleled inhibitor ( Moenomycin binds in the active site cleft of PGT; sugar rings E and F and the phosphoglycerate (unit G; Figure 1 ) make hydrogen-bond contacts with highly conserved or invariant amino acid residues essential for PGT activity. Thus, a mutation that would decrease the binding efficiency of MmA is likely to inactive the PGT. Previous attempts at modifying the E and F sugars or the phosphoglycerate unit itself have resulted in a loss of activity (Welzel, 2005) . These core interactions add the most specificity to the Mm's. Flexibility further away from the phosphoglycerate has resulted in two minimal bioactive pharmacophores: both the C-E-F and D-E-F trisaccharides with C 25 -length lipid chains (Welzel, 2005; Yuan et al., 2008) .
Despite its advantages, MmA suffers from poor pharmokinetics, probably as a result of the C 25 lipid chain, which has been shown to bind excessively to serum (Pfaller, 2006) . In the Mtg-MmA co-complex, the initial portion of the lipid tail forms hydrophobic contacts to the enzyme (Heaslet et al., 2009) ; the rest of the moenocinol is likely to anchor MmA to the membrane to facilitate interactions with PGTs. In vitro, inhibitory activity of a delipidated derivative of MmA (4, Figure 1 ) decreases 100-fold, yet its potency is still comparable to that of clinically useful glycopeptides. Unfortunately, in vivo antibacterial activity of the delipidated MmA is completely abolished (Chen et al., 2003) . Likewise, an MmA analog containing C 10 lipid (5; Figure 1 ) is shown to efficiently inhibit PGTs in vitro, although its antibacterial activity in vivo is negligible (Adachi et al., 2006) . Recently, C 15 lipid Mm's were produced heterologously and shown to possess measurable antibiotic activity, establishing a minimum lipid length required for in vivo activity (Ostash et al., 2009) . Overall, MmA appears to be uniquely shaped to fit the PGT active site, and the available structural information will aid in the structure-based design of improved PGT inhibitors.
Biosynthesis of MmA: unusual biotransformations and novel derivatives
The biosynthetic origins of some components of MmA were determined by Welzel and coworkers through extensive feeding experiments. Specifically, it was shown that chromophore unit A and the lipid tail of MmA derive from 5-aminolevulinic acid (Shemin pathway) and isoprenoid metabolism (non-mevalonate or DOXP pathway), respectively (Welzel, 2005) . Analysis of UV-induced S. ghanaensis mutants provided some evidence for production of menomycins with altered lipid and carbohydrate portions; however, none were rigorously characterized (Subramaniam-Niehaus et al., 1997) .
Identification of the MmA biosynthetic genes (moe) was not trivial owing to the structural and, subsequently, biogenetic uniqueness of the molecule. By combining PCR and whole-genome scanning strategies, the genes for MmA production were identified only recently (Ostash et al., 2007) . The genetic organization of the moe genes does not resemble that of a typical antibiotic gene cluster (Figure 3) . First, the moe genes actually form two clusters located on opposite ends of the S. ghanaensis chromosome. Second, they show little or no homology to other known antibiotic biosynthetic genes, explaining why PCR strategies alone failed to identify them. Finally, sequence analysis and heterologous expression experiments show that there are no regulatory or resistance genes within either of the moe clusters. Most of moe cluster 1 was heterologously expressed in Streptomyces lividans TK24 to produce compound 2 (Ostash et al., 2007 ; Figure  1) . Coexpressing or deleting genes in this heterologous system led to the identification and biosynthetic assignment of all genes necessary to produce MmA (Ostash et al., 2009) .
Combining genetics and biochemistry, the 17-step MmA biosynthetic pathway was outlined utilizing the heterologous expression system (summarized in Figure 3 ). Coupling of 3-phosphoglycerate (3-PG) to a C 15 isoprene moiety is followed by subsequent glycosylations, sugar and lipid tailoring, and chromophore attachment. In an unprecedented reaction in bacterial metabolism, enzyme MoeO5 controls the formation of the initial z-farnesyl-3-PG intermediate in MmA biosynthesis (Ostash et al., 2009 ). MoeO5 shows low homology to isoprenylglyceryl diphosphate synthases from Archaea, which couple either C 20 or C 25 isoprene chains to sn-glycerol-1-phosphate in the first dedicated step in the synthesis of Archaeal membrane lipids (Payandeh et al., 2006) . z-farnesyl-3-PG serves as an acceptor substrate for the first Moe glycosyltransferase and, later in the pathway, a second prenylsynthase MoeN5. The latter incorporates a C 10 isoprene unit into the glycosylated MmA precursor and is responsible for the unusual rearrangement within the C 25 lipid chain of MmA.
Of the five glycosyltransferases (GTs) in the moe clusters, only MoeGT1, responsible for the initial glycosylation, is predicted to contain a typical GT-B superfamily fold (Ostash et al., 2007) . After MoeE5 epimerizes UDP-glucuronic acid (UDP-GlcUA) to UDP-galacturonic acid (UDP-GalUA), MoeGT1 attaches UDP-GalUA to the z-farnesyl-3PG scaffold. Then, a number of interesting biotransformations occur to make carbohydrate unit F the most heavily modified sugar in MmA. First, MoeF5 converts the carboxylic acid to a carboxyamide, a step that is required before subsequent biosynthetic enzymes can act. MoeK5, a putative SAM-radical enzyme, methylates at the C4 position of the F ring but is not required for bioactivity or formation of a pentasaccharide Mm (Figure 3 ; Ostash et al., 2009 ). Analyses of intermediates in gene deletion studies indicate that after a trisaccharide is formed, the C3 position of unit F is carbamoylated by MoeM5 a step that is vital for bioactivity as the carbamoyl unit makes essential contacts with PGTs (Ostash et al., 2007) .
The other four GTs were more difficult to identify in silico and are not homologous to other GTs from bacterial secondary metabolism (Ostash et al., 2007) . However, all of these enzymes are capable of utilizing UDP-sugars from primary metabolism. Purification of MmA intermediates from the heterologous expression of subsets of moe genes in S. lividans identified the function of each GT and the order in which they act. MoeGT4 is the second GT and attaches UDP-GlcNAc (unit E) to the growing scaffold. Either MoeGT5 or MoeGT3 can then attach the C or D rings, respectively, and, after both sugars have been added, MoeGT2 attaches UDP-GalUA (unit B) to form the pentasaccharide (Ostash et al., 2009 ; Figure 3 ).
The availability of moe genes opens the door for in-depth studies on the biosynthesis of phosphoglycolipid antibiotics, and initial experiments have already led to the generation of structurally complex and bioactive MmA fragments. These experiments have already explained much of the structural diversity found in complexes of Mm's produced in fermentation (see above). With the exception of F ring carboxyamidation, the degree of tailoring of individual sugar rings does not affect downstream glycosylation steps, and the latter are independent of the length of the lipid chain. Therefore, combinatorial biosynthesis of Mm's with varying numbers of sugar rings and modifications is feasible.
Regulation of MmA biosynthesis
S. ghanaensis, as well as current heterologous producers, accumulate low amounts of Mm's making in vivo activity studies difficult (Yuan et al., 2008; Ostash et al., 2009) . Therefore, the development of approaches for the overproduction of Mm's is vital to further studies of phosphoglycolipid libraries. Neither moe clusters 1 nor 2 contain the pathway-specific regulatory genes usually found in streptomycete antibiotic gene clusters. However, inspection of sequences in moe cluster 1 revealed the presence of TTA codons within coding regions of several moe genes -moeO5, moeE5, moeR5 (Ostash et al., 2007) . This codon is the rarest in the GC-rich genomes of streptomycetes, and because its tRNA counterpart is available only in the late stationary phase of growth, the translation of mRNAs containing UUAcodons is temporally limited (Chater, 2006) . Two of the TTA q moe genes, moeO5 and moeE5, control the first steps of MmA assembly and are the first genes in their respective moe operons (Figure 3) . Therefore, TTA codons can regulate MmA biosynthesis at the level of translation of corresponding polycistronic mRNA. In addition, an in silico analysis of the partially sequenced S. ghanaensis genome (www.broad. mit.edu / annotation / genome / streptomyces _ group) revealed many orthologs of known pleiotropic regulators for secondary metabolism in model strain S. coelicolor (Bibb, 2005) . These genes are as yet unexplored targets for research programs focused on improving MmA production.
MmA resistance mechanisms in target and producing bacteria
Moenomycins have been used in animal nutrition for more than 30 years, and yet no data exist on the isolation and characterization of mutants displaying high-level resistance to MmA (Pfaller, 2006) . The isolation of MmA-intermediateresistant cocci under laboratory conditions has been reported by several groups (Huber, 1979; Nishi et al., 2003) . The described MmA-resistant mutants do not carry mutations in PGT genes, and the level of PGT expression is unchanged (Nishi et al., 2003) . The resistance is probably as a result of either a thickened cell wall or mutations in genes fmtC and lysC that control the biosynthesis of lysyl-phosphatidylglycerol, a positively charged component of the cell membrane. It is hypothesized that cells having thicker sacculus or a more negatively charged cytoplasmic membrane are more efficient in preventing MmA from reaching and binding the PGTs (Nishi et al., 2004) . This indicates a rather nonspecific resistance mechanism; indeed, the aforementioned MmA-resistant bacteria show decreased susceptibility to vancomycin, and the fmtC mutants are more sensitive to cationic peptides (defensins, CAP18) and the positively charged aminoglycoside gentamycin. Recent research on the ruminal microbe Prevotella bryantii adapted to elevated concentrations of moenomycin also suggests that changes in cell wall composition, namely increased availability of undecaprenylpyrophosphate, can account for resistance to MmA, as well as to vancomycin and bacitracin (Edwards et al., 2008) .
In actinomycetes, resistance genes are often clustered with the genes for biosynthesis of the relevant antibiotic, and their identification generally provides valuable insights into the evolution and dissemination of antibiotic resistance among pathogens. However, S. ghanaensis does not contain any obvious genetic determinants of MmA resistance within either moe cluster. Actinomycetes that do not naturally produce any Mm's, such as S. lividans and S. coelicolor, are also resistant to MmA. Although extensive studies on Actinomycete PGTs have not been done, the essential amino acid residues of PGTs are well known (Goffin and Ghuysen, 1998) , and there is no bioinformatic evidence that S. coelicolor has evolved MmA-resistant PGTs (B. Ostash, unpublished data). Therefore, as seems to be the case for cocci and Prevotella, MmA resistance in actinomycetes can stem from general as-yet-unknown peculiarities in the composition of their cell wall and/or membrane.
Outlook
MmA is an appealing starting point for antibiotic development, as it is fairly atoxic and very potent (Huber, 1979) . It is difficult to produce improved moenomycins chemically, and exploitation of the moenomycin biosynthetic machinery can significantly speed up that process. Recent studies show that it is possible to produce structurally complex and bioactive analogs of MmA through fermentation (Ostash et al., 2009) ; their further diversification can be achieved via chemical or chemoenzymatic strategies. Therefore, the generation of small libraries of Mm's can now be pursued. Much remains to be learned about how to overproduce and purify these novel compounds from actinomycetes. However, the full sequence of the S. ghanaensis genome and the ability to heterologously express the moe genes should help approach this issue rationally. MmA resistance remains unexplored, despite the importance of understanding resistance mechanisms for the development of clinical PGT inhibitors. Obviously, more extensive studies are needed to elucidate possible routes of the evolution for moenomycin resistance in bacteria.
It is essential to realize that natural products are a valuable and finite resource. Their use in animal nutrition has to be vigorously questioned in times when medicine faces pathogens that are resistant to virtually all available drugs. Antimicrobial growth promoters trigger the evolution and dissemination of antibiotic resistance determinants among animal bacteria (Butaye et al., 2003) , eventually narrowing down the options for the treatment of life-threatening human diseases. In this regard, the worldwide trend to ban moenomycins and other antibiotics in animal nutrition is a welcome move, which could allow us to prevent the disasters of the pre-antibiotic era.
